These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30333119)

  • 21. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
    Iurlo A; Cattaneo D; Gianelli U
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicenter study of 55 patients. Groupe Français de Cytogénétique Hématologique.
    Cancer Genet Cytogenet; 1988 Jun; 32(2):157-68. PubMed ID: 3163258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What are the molecular mechanisms driving the switch from MPNs to leukemia?
    Wang X; Hoffman R
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.
    Lin P; Jones D; Medeiros LJ; Chen W; Vega-Vazquez F; Luthra R
    Am J Clin Pathol; 2006 Oct; 126(4):530-3. PubMed ID: 16938665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.
    Mayeur-Rousse C; Sorel N; Voldoire M; Canioni D; Brizard F; Randriamalala E; Turhan AG; Chomel JC
    Leuk Res; 2012 Mar; 36(3):377-81. PubMed ID: 22030335
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
    Kennedy JA; Atenafu EG; Messner HA; Craddock KJ; Brandwein JM; Lipton JH; Minden MD; Schimmer AD; Schuh AC; Yee KW; Gupta V
    Blood; 2013 Apr; 121(14):2725-33. PubMed ID: 23361905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
    Mahdi D; Spiers J; Rampotas A; Polverelli N; McLornan DP
    Br J Haematol; 2023 Oct; 203(2):169-181. PubMed ID: 37527977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms.
    McLornan DP; Harrison CN
    Br J Haematol; 2020 Oct; 191(1):21-36. PubMed ID: 32167592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation.
    Soliman DS; Amer AM; Mudawi D; Al-Sabbagh Z; Alkuwari E; Al-Sabbagh A; Ibrahim F; Yassin MA
    Acta Biomed; 2018 Apr; 89(3-S):38-44. PubMed ID: 29633732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
    Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
    Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
    Khan M; Siddiqi R; Gangat N
    Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis.
    Han X; Medeiros LJ; Abruzzo LV; Jones D; Lin P
    Am J Clin Pathol; 2006 Jan; 125(1):49-56. PubMed ID: 16482991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
    Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
    Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Thoennissen NH; Krug UO; Lee DH; Kawamata N; Iwanski GB; Lasho T; Weiss T; Nowak D; Koren-Michowitz M; Kato M; Sanada M; Shih LY; Nagler A; Raynaud SD; Müller-Tidow C; Mesa R; Haferlach T; Gilliland DG; Tefferi A; Ogawa S; Koeffler HP
    Blood; 2010 Apr; 115(14):2882-90. PubMed ID: 20068225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
    Castillo Tokumori F; Al Ali N; Chan O; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e521-e525. PubMed ID: 35241387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Shah MV; Saliba RM; Varma A; Ciurea SO; Oran B; Olson A; Bose P; Bashir Q; Masarova L; Alousi AM; Srour S; Mehta RS; Daver N; Pemmaraju N; Verstovsek S; Champlin RE; Popat UR
    Br J Haematol; 2021 Jun; 193(5):1004-1008. PubMed ID: 33821472
    [No Abstract]   [Full Text] [Related]  

  • 40. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
    Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T
    J Cell Mol Med; 2009 Aug; 13(8A):1437-50. PubMed ID: 19522842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.